NasdaqGS:HALOBiotechs
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO)
In May 2026, Halozyme Therapeutics, Inc. reported first-quarter 2026 results showing revenue of US$376.71 million and net income of US$150.05 million, reaffirmed its 2026 revenue guidance of US$1.71 billion to US$1.81 billion, announced a new share repurchase authorization of up to US$1.00 billion through 2028, and confirmed completion of a prior buyback program.
Earlier that month, GSK announced a global collaboration and license agreement to use Halozyme’s ENHANZE technology across...